Leukaemogenic and mutagenic activity of the butyrophenon, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone (haloperidol).
Development of mainly monocytic-myeloid leukaemias was observed in two strains of mice upon i.p. administration of 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone (haloperidol), an antipsychotic drug. Haloperidol was also shown to be mutagenic in the Ames Salmonella test system.
D000818:Animals; D006220:Haloperidol / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D007942:Leukemia, Experimental / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009152:Mutagenicity Tests; D051381:Rats; D012306:Risk; D012486:Salmonella typhimurium / Q000187:drug effects / Q000235:genetics
D006220:Haloperidol